AMPLY Discovery secures strategic investment from Keeps Biomed to bolster oncology programmes.
The biotechnology funding pairs strategic capital with a collaborative agreement to explore oncology opportunities.
AMPLY Discovery is an artificial intelligence driven drug discovery company based in the United Kingdom. The firm leverages multi-omic datasets and laboratory testing to generate therapeutic programmes for partnering.
AMPLY Discovery has secured strategic investment from Keeps Biomed to support its oncology pipeline and biotechnology initiatives. The funding round pairs financial backing with a collaborative agreement to explore oncology projects between the two companies. Alongside the investment, AMPLY appointed Dr Oliver Rausch as chief scientific officer to accelerate target validation.
The firm applies artificial intelligence to mine genomic datasets and validate findings through laboratory testing. Spun out of Queen's University Belfast, AMPLY operates a portfolio model aimed at producing licensable assets in areas of high unmet medical need.
From the founder
"This strategic investment is an important endorsement of AMPLY's platform and our approach to oncology. We're building a company designed for partnering – generating high-quality, data-driven programmes and taking them to clear inflection points. We're delighted to welcome Keeps Biomed as a strategic investor, and to bring Oliver on board as CSO to help sharpen our oncology execution and partnering readiness."
Ben Thomas
CEO at AMPLY Discovery
Investor perspective
"We see significant opportunity in applying advanced AI-enabled discovery approaches to build a differentiated oncology pipeline. AMPLY's platform and team align strongly with our strategic direction, and we look forward to developing collaboration opportunities in oncology."
Ha Kim
CEO, Keeps Biomed
Use of funds
- 01Fund research and development
- 02Continue product development
Investors
Categories
About the company
AMPLY Discovery
AMPLY Discovery develops therapeutic programmes using artificial intelligence and experimental testing.